Skip to main content
SpringerLink
Log in

Peniskarzinom

Penile cancer

  • Originalien
  • Published:
Journal für Urologie und Urogynäkologie/Österreich Aims and scope

Zusammenfassung

Beim Peniskarzinom handelt es sich fast immer um ein aggressives Plattenepithelkarzinom, welches typischerweise an der Glans oder am inneren Vorhautblatt entsteht. Es stellt aufgrund seiner geringen Inzidenz von 1/100.000 Männern in Europa eine Besonderheit im klinisch-urologischen Alltag dar. Im Jahre 2015 wurden in Österreich nur 65 Peniskarzinome neu diagnostiziert. Aufgrund der Seltenheit dieser Erkrankung und der damit verbundenen Problematik in Diagnostik und Therapie wurde die Behandlung des Peniskarzinoms in mehreren Ländern zentralisiert.

Abstract

Penile cancer is almost always an aggressive squamous cell carcinoma that typically develops on the glans or inner foreskin. Given its low incidence in Europe of 1/100,000 males, it represents a rare entity in clinical urological routine. In 2015, only 65 cases of penile cancer were newly diagnosed in Austria. Due to the rarity of this disease and the associated problems in diagnosis and therapy, a number of countries have centralized the treatment of penile cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Hakenberg OW, Compérat EM, Minhas S, Necchi A, Protzel C, Watkin N (2015) EAU guidelines on penile cancer: 2014 update. Eur Urol 67(1):142–150

    Article  PubMed  Google Scholar 

  2. Madsen BS, van den Brule AJ, Jensen HL, Wohlfahrt J, Frisch M (2008) Risk factors for squamous cell carcinoma of the penis—population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev 17(10):2683–2691

    Article  CAS  PubMed  Google Scholar 

  3. Maden C, Sherman KJ, Beckmann AM, Hislop TG, Teh CZ, Ashley RL, Daling JR (1993) History of circumcision, medical conditions, and sexual activity and risk of penile cancer. J Natl Cancer Inst 85(1):19–24

    Article  CAS  PubMed  Google Scholar 

  4. Parkin DM, Bray F (2006) Chapter 2: The burden of HPV-related cancers. Vaccine 24(Suppl 3):11–25

    Article  Google Scholar 

  5. Rubin MA, Kleter B, Zhou M, Ayala G, Cubilla AL, Quint WG, Pirog EC (2001) Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol 159(4):1211–1218

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Hellner K, Dorrell L (2017) Recent advances in understanding and preventing human papillomavirus-related disease. F1000Res. https://doi.org/10.12688/f1000research.9701.1

    Article  PubMed  PubMed Central  Google Scholar 

  7. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT (1992) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89(24):12180–12184

    Article  CAS  PubMed  Google Scholar 

  8. Castellsague X, Giuliano AR, Goldstone S, Guevara A, Mogensen O, Palefsky JM, Group T, Shields C, Liu K, Maansson R et al (2015) Immunogenicity and safety of the 9‑valent HPV vaccine in men. Vaccine 33(48):6892–6901

    Article  CAS  PubMed  Google Scholar 

  9. Bundesministerium für Soziales, Gesundheit, Pflege und Konsumentenschutz (2019) Impfplan Österreich 2019. https://www.paediatrie.at/phocadownloadpap/impfplan___oesterreich_2019.pdf. Zugegriffen: 20.1.2019

  10. Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, Luna J, Myers E, Mallary S, Bautista OM et al (2011) End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer 105(1):28–37

    Article  PubMed  PubMed Central  Google Scholar 

  11. Gottlieb J, Higley C, Sosnowski R, Bjurlin MA (2016) Smoking-related genitourinary cancers: a global call to action in smoking cessation. Rev Urol 18(4):194–204

    PubMed  PubMed Central  Google Scholar 

  12. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, Carter JJ, Porter PL, Galloway DA, McDougall JK et al (2005) Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. Int J Cancer 116(4):606–616

    Article  CAS  PubMed  Google Scholar 

  13. Stern RS (1990) Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation. The photochemotherapy follow-up study. N Engl J Med 322(16):1093–1097

    Article  CAS  PubMed  Google Scholar 

  14. Visser O, Adolfsson J, Rossi S, Verne J, Gatta G, Maffezzini M, Franks KN, The RARECARE working group (2012) Incidence and survival of rare urogenital cancers in Europe. Eur J Cancer 48(4):456–464

    Article  CAS  PubMed  Google Scholar 

  15. Bray F, Ferlay J, Laversanne M, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R, Antoni S et al (2015) Cancer incidence in five continents: inclusion criteria, highlights from volume X and the global status of cancer registration. Int J Cancer 137(9):2060–2071

    Article  CAS  PubMed  Google Scholar 

  16. Backes DM, Kurman RJ, Pimenta JM, Smith JS (2009) Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control 20(4):449–457

    Article  PubMed  Google Scholar 

  17. Chaux A, Netto GJ, Rodriguez IM, Barreto JE, Oertell J, Ocampos S, Boggino H, Codas R, Xavier Bosch F, de Sanjose S et al (2013) Epidemiologic profile, sexual history, pathologic features, and human papillomavirus status of 103 patients with penile carcinoma. World J Urol 31(4):861–867

    Article  PubMed  Google Scholar 

  18. Verhoeven RH, Janssen-Heijnen ML, Saum KU, Zanetti R, Caldarella A, Holleczek B, Brewster DH, Hakulinen T, Horenblas S, Brenner H et al (2013) Population-based survival of penile cancer patients in Europe and the United States of America: no improvement since 1990. Eur J Cancer 49(6):1414–1421

    Article  CAS  PubMed  Google Scholar 

  19. Trama A, Foschi R, Larranaga N, Sant M, Fuentes-Raspall R, Serraino D, Tavilla A, Van Eycken L, Nicolai N, EUROCARE‑5 Working Group (2015) Survival of male genital cancers (prostate, testis and penis) in Europe 1999–2007: results from the EUROCARE‑5 study. Eur J Cancer 51(15):2206–2216

    Article  PubMed  Google Scholar 

  20. Dechev IY, Banchev AV, Mateva NG (2005) Epidemiology, diagnostic and therapeutic problems for carcinoma of the penis in the regions of Plovdiv, Pazardzhik and Smolyan between 1993 and 2002. Folia Med 47(3–4):33–39

    Google Scholar 

  21. Jakobsen JK, Krarup KP, Kirrander P, Håkansson U, Kaipia A, Perttila I, Axcrona K, Torkelsen TK, Hilmarsson R, Jensen JB et al (2016) Penile cancer in Scandinavia: current practice and future perspectives. Scand J Urol 50(1):90–92

    Article  PubMed  Google Scholar 

  22. Djajadiningrat RS, Graafland NM, van Werkhoven E, Meinhardt W, Bex A, van der Poel HG, van Boven HH, Valdés Olmos RA, Horenblas S (2014) Contemporary management of regional nodes in penile cancer-improvement of survival? J Urol 191(1):68–73

    Article  PubMed  Google Scholar 

  23. Bayles AC, Sethia KK (2010) The impact of Improving Outcomes Guidance on the management and outcomes of patients with carcinoma of the penis. Ann R Coll Surg Engl 92(1):44–45

    Article  PubMed  PubMed Central  Google Scholar 

  24. Veeratterapillay R, Teo L, Asterling S, Greene D (2015) Oncologic outcomes of penile cancer treatment at a UK supraregional center. Urology 85(5):1097–1103

    Article  PubMed  Google Scholar 

  25. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2020) S3-Leitlinie Diagnostik, Therapie und Nachsorge des Peniskarzinoms, Langversion 1.01 Konsultationsfassung. https://www.leitlinienprogramm-onkologie.de/leitlinien/peniskarzinom/. Zugegriffen: 22. Apr. 2020 (AWMF Registernummer: 043-042OL)

  26. Heins MJ, de Jong JD, Spronk I, Ho VKY, Brink M, Korevaar JC (2017) Adherence to cancer treatment guidelines: influence of general and cancer—specific guideline characteristics. Eur J Public Health 27(4):616–620

    PubMed  Google Scholar 

  27. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR (1999) Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 282(15):1458–1465

    Article  CAS  PubMed  Google Scholar 

  28. Rieken M, Djajadiningrat RS, Kluth LA, Favaretto RL, Xylinas E, Guimaraes GC, Soares FA, Kent M, Sjoberg DD, Horenblas S et al (2014) Predictors of cancer-specific mortality after disease recurrence in patients with squamous cell carcinoma of the penis. Eur Urol 66(5):811–814

    Article  PubMed  Google Scholar 

  29. Kieffer JM, Djajadiningrat RS, van Muilekom EA, Graafland NM, Horenblas S, Aaronson NK (2014) Quality of life for patients treated for penile cancer. J Urol 192(4):1105–1110

    Article  PubMed  Google Scholar 

  30. Klaassen Z, Jen RP, DiBianco JM, Reinstatler L, Li Q, Madi R, Lewis RW, Smith AM, Neal DE Jr, Moses KA et al (2015) Factors associated with suicide in patients with genitourinary malignancies. Cancer 121(11):1864–1872

    Article  PubMed  Google Scholar 

  31. Simpson WG, Klaassen Z, Jen RP, Hughes WM 5th, Neal DE Jr, Terris MK (2018) Analysis of suicide risk in patients with penile cancer and review of the literature. Clin Genitourin Cancer 16(2):e257–e261

    Article  PubMed  Google Scholar 

  32. Cindolo L, Spiess PE, Bada M, Chipollini JJ, Nyirady P, Chiodini P, Varga J, Ditonno P, Battaglia M, De Nunzio C et al (2018) Adherence to EAU guidelines on penile cancer translates into better outcomes: a multicenter international study. World J Urol 37(8):1649–1657

    Article  PubMed  Google Scholar 

  33. Albersen M, Parnham A, Joniau S, Sahdev V, Christodoulidou M, Castiglione F, Nigam R, Malone P, Freeman A, Jameson C et al (2018) Predictive factors for local recurrence after glansectomy and neoglans reconstruction for penile squamous cell carcinoma. Urol Oncol 36(4):141–146

    Article  PubMed  Google Scholar 

  34. Horenblas S (2001) Lymphadenectomy for squamous cell carcinoma of the penis. Part 2: the role and technique of lymph node dissection. BJU Int 88(5):473–483

    Article  CAS  PubMed  Google Scholar 

  35. Kirrander P, Sherif A, Friedrich B, Lambe M, Håkansson U (2016) Swedish National Penile Cancer Register: incidence, tumour characteristics, management and survival. BJU Int 117(2):287–292

    Article  PubMed  Google Scholar 

  36. Jakobsen JK, Jensen JB (2016) DaPeCa-2: implementation of fast-track clinical pathways for penile cancer shortens waiting time and accelerates the diagnostic process—a comparative before-and-after study in a tertiary referral centre in Denmark. Scand J Urol 50(1):80–87

    Article  PubMed  Google Scholar 

  37. Statistik Austria (2018) Jahrbuch der Gesundheitsstatistik 2016. http://www.statistik.at/web_de/services/publikationen/4/index.html. Zugegriffen: 20.1.2019

  38. Spiess PE, Hernandez MS, Pettaway CA (2009) Contemporary inguinal lymph node dissection: minimizing complications. World J Urol 27(2):205–212

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung für Urologie, SMZ-Ost/Donauspital, Wien, Österreich

    Klaus Eredics &  Martin Marszalek

  2. Urologische Abteilung, Landesklinikum Baden-Mödling, Baden, Österreich

    Stephan Seklehner

  3. Paracelsus Medizinische Privatuniversität, Salzburg, Österreich

    Stephan Seklehner

Authors
  1. Klaus Eredics
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephan Seklehner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin Marszalek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Marszalek.

Ethics declarations

Interessenkonflikt

K. Eredics, S. Seklehner und M. Marszalek geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Hinweis des Verlags

Der Verlag bleibt in Hinblick auf geografische Zuordnungen und Gebietsbezeichnungen in veröffentlichten Karten und Institutsadressen neutral.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eredics, K., Seklehner, S. & Marszalek, M. Peniskarzinom. J. Urol. Urogynäkol. AT 27, 75–78 (2020). https://doi.org/10.1007/s41972-020-00106-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s41972-020-00106-6

Schlüsselwörter

Keywords

Search

Navigation